ImmunoBrain

Israel
Ness Ziona, Central District, Israel, 7414002

Company profile

ImmunoBrain company profile

ImmunoBrain is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. ImmunoBrain’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. ImmunoBrain's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
7414002
Country code
IL
Continent
Asia

Capital profile

Funding and company signals

Funding rounds
3
Last funding
Grant / $5M / 2021-08-27
Investors
3
Lead investors
3
Articles
8

Founders and investors

Lead investors

Alzheimer's AssociationNational Institutes of HealthThe ALS Association

Investors

Alzheimer's AssociationNational Institutes of HealthThe ALS Association